Niraparib (MK-4827) hydrochloride | PARP Inhibitor

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

CAS No. :	1038915-64-8
Formula :	C₁₉H₂₁ClN₄O
M.W :	356.85
SMILES Code :	O=C(C1=CC=CC2=CN(C3=CC=C([C@H]4CNCCC4)C=C3)N=C12)N.[H]Cl
Synonyms :	MK-4827 hydrochloride; Niraparib hydrochloride
MDL No. :	MFCD20502397

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H302-H340
Precautionary Statements:	P260-P264-P270-P280-P281-P330-P301+P312-P405-P501

HT-1080	10 µM	4 h	To evaluate the sensitivity of STS cell lines to Niraparib, results showed that STS cell lines were sensitive to Niraparib.	PMC7449912
HT-1080	10 µM	48 h	To evaluate the effect of Niraparib on cell cycle and apoptosis, results showed that Niraparib treatment caused cell cycle arrest and increased apoptosis.	PMC7449912
ovarian and maμMary tumor cells	2 μM	12 hours	Niraparib induced tumor cell death via the ATM-AMPK-ULK1 pathway, leading to mTOR inactivation and autophagosome formation	PMC6154859
SKOV3	10 μM	48 h	To investigate the effect of PARP inhibitors on PD-L1 protein expression, results showed that Niraparib upregulated PD-L1 expression.	PMC8499579
UWB1.289	10 μM	48 h	To investigate the effect of PARP inhibitors on PD-L1 protein expression, results showed that Niraparib upregulated PD-L1 expression.	PMC8499579
MIA PaCa-2	26 µM	48 hours	Niraparib showed stronger antitumor effects than Olaparib in MIA PaCa-2 cells with an IC50 of 26 µM.	PMC9618811
PANC-1	50 µM	48 hours	Niraparib showed stronger antitumor effects than Olaparib in PANC-1 cells with an IC50 of 50 µM.	PMC9618811
Capan-1	15 µM	48 hours	Niraparib showed stronger antitumor effects than Olaparib in Capan-1 cells with an IC50 of 15 µM.	PMC9618811
OVCAR8	20 µM	48 hours	Niraparib showed stronger antitumor effects than Olaparib in OVCAR8 cells with an IC50 of 20 µM.	PMC9618811
PEO1	28 µM	48 hours	Niraparib showed stronger antitumor effects than Olaparib in PEO1 cells with an IC50 of 28 µM.	PMC9618811
Breast and ovarian cancer cell lines	10,000 nM to 0.3 nM	10 days	To evaluate the anti-proliferative activity of the combination of PRMT5 and PARP inhibitors, the results showed significant growth inhibition and cytotoxicity in breast and ovarian cancer cell lines.	PMC10436459
Breast and ovarian cancer cell lines	5000 nM to 8 nM	14 days	To evaluate the anti-proliferative activity of the combination of PRMT5 and PARP inhibitors through long-term exposure, the results showed significant growth inhibition and cytotoxicity in breast and ovarian cancer cell lines.	PMC10436459
breast cancer cell lines	10,000 nM to 0.3 nM	10 days	To evaluate the anti-proliferative effects of the combination of Niraparib and PRMT5 inhibitor GSK3326595, synergistic effects were observed in breast cancer cell lines.	PMC10436459
ovarian cancer cell lines	10,000 nM to 0.3 nM	10 days	To evaluate the anti-proliferative effects of the combination of Niraparib and PRMT5 inhibitor GSK3326595, synergistic effects were observed in ovarian cancer cell lines.	PMC10436459
Ovarian cancer cells	2 μM	12 hours	Niraparib killed tumor cells via an ATM-AMPK-ULK1 pathway, resulting in mTOR inactivation and the formation of autophagosomes, followed by autolysosome formation.	PMC6154859
Breast cancer cells	2 μM	12 hours	Niraparib killed tumor cells via an ATM-AMPK-ULK1 pathway, resulting in mTOR inactivation and the formation of autophagosomes, followed by autolysosome formation.	PMC6154859

Mice	CDX and PDX models	Oral	50 mg/kg sulforaphane daily, 10 mg/kg docetaxel weekly	daily sulforaphane, weekly docetaxel, continuous treatment	To evaluate the effect of Niraparib and TMZ combination therapy, results showed that the combination significantly inhibited tumor growth.	PMC7449912
athymic mice	BT474 mammary tumor model	oral	25 mg/kg or 50 mg/kg	Every three days, for four weeks	Niraparib significantly slowed the growth of BT474 tumors, but the growth delay was only approximately equivalent to the duration of drug exposure	PMC6154859
mice	ovarian cancer model	oral	Niraparib 50 mg/kg, Irinotecan 10 mg/kg	Niraparib orally for 5 days a week, Irinotecan intraperitoneally for 2 days a week, for 4 weeks	To investigate the effect of Niraparib on PD-L1 expression and its synergistic effect with PD-L1 blockade, results showed that Niraparib increased PD-L1 expression and combined with PD-L1 blockade could more effectively inhibit tumor growth.	PMC8499579
C57BL/6 mice	ID8 ovarian cancer model	Intraperitoneal injection	25 mg/kg	once daily for 5 days	Evaluate the anti-tumor effects of Niraparib in combination with NRT	PMC11380394
Mice	MDA-MB-468 and OVCAR3 xenograft models	Oral	25 mg/kg	four times a week for 8 weeks	To evaluate the anti-tumor activity of the combination of PRMT5 and PARP inhibitors in vivo, the results showed significant tumor growth inhibition and tumor stasis and regression in MDA-MB-468 and OVCAR3 xenograft models.	PMC10436459
BALB/C nude mice	CDX model	oral	50 mg/kg/day	Once daily for 3 days	To evaluate the effect of Niraparib and TMZ combination therapy on tumor growth in CDX models, results showed that the combination significantly inhibited tumor growth	PMC7449912
Mice	C57BL/6 mice	Oral	GSK3326595: 50 mg/kg, Niraparib: 35 mg/kg	GSK3326595: Twice daily, Niraparib: Once daily, until the end of the experiment	To investigate the anti-tumor effect of Niraparib combined with PD-L1 blockade, results showed that the combination significantly inhibited tumor growth.	PMC8499579
C57BL/6 mice	ID8 ovarian cancer model	Intraperitoneal injection	100 mg/kg	once daily for 5 days/week	Evaluate the anti-tumor effects of Niraparib in combination with NRT	PMC11380394
mice	MDA-MB-468 breast cancer and OVCAR-3 ovarian cancer xenograft models	oral	25 mg/kg	4 times per week for 8 weeks	To evaluate the tumor growth inhibition effects of the combination of Niraparib and PRMT5 inhibitor GSK3326595, tumor stasis was observed in the MDA-MB-468 model and tumor regression was observed in the OVCAR-3 model.	PMC10436459
Athymic mice	BT474 breast cancer model	Oral	50 mg/kg/day	Once daily for 3 days	Niraparib significantly slowed the growth of BT474 tumors, but the growth delay caused by niraparib alone was only approximately equivalent to the prior duration of drug exposure.	PMC6154859

{[proInfo.proName]}

CAS No.: 1038915-64-8

{[proInfo.proName]}

CAS No.: 1038915-64-8

Alternative Products

Product Details of Niraparib HCl

Safety of Niraparib HCl

Related Pathways of Niraparib HCl

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed